United Therapeutics Stock Total Asset
| UTH Stock | EUR 352.40 6.20 1.79% |
United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.
United |
United Therapeutics Company Total Asset Analysis
United Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current United Therapeutics Total Asset | 6.04 B |
Most of United Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, United Therapeutics has a Total Asset of 6.04 B. This is 19.62% lower than that of the Healthcare sector and 205.92% higher than that of the Biotechnology industry. The total asset for all Germany stocks is 79.49% higher than that of the company.
United Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.United Therapeutics is currently under evaluation in total asset category among its peers.
United Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.38 % | |||
| Operating Margin | 0.51 % | |||
| Current Valuation | 10.24 B | |||
| Shares Outstanding | 46.3 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Price To Earning | 7.31 X | |||
| Price To Book | 2.73 X | |||
| Price To Sales | 6.30 X | |||
| Revenue | 1.94 B | |||
| Gross Profit | 1.78 B | |||
| EBITDA | 1.03 B | |||
| Net Income | 727.3 M | |||
| Cash And Equivalents | 1.79 B | |||
| Cash Per Share | 40.73 X | |||
| Total Debt | 800 M | |||
| Debt To Equity | 41.30 % | |||
| Current Ratio | 4.62 X | |||
| Book Value Per Share | 104.20 X | |||
| Cash Flow From Operations | 802.5 M | |||
| Earnings Per Share | 13.25 X | |||
| Price To Earnings To Growth | 1.00 X | |||
| Target Price | 231.89 | |||
| Number Of Employees | 965 | |||
| Beta | 0.63 | |||
| Market Capitalization | 10.75 B | |||
| Total Asset | 6.04 B | |||
| Z Score | 7.8 | |||
| Net Asset | 6.04 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in United Stock
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in United Stock please use our How to Invest in United Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.